Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy

Charles Dumontet, Sylvie Isaac, Pierre Jean Souquet, Françoise Bejui-Thivolet, Yves Pacheco, Nadine Peloux, Anthony Frankfurter, Richard Luduena, Maurice Perol

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total β tubulin, classes I, II and III β tubulin isotypes, δ2 alpha tubulin, τ protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-β tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. δ2 alpha tubulin, τ protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p=0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p= 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

Original languageEnglish (US)
Pages (from-to)58-64
Number of pages7
JournalElectronic Journal of Oncology
Issue number1
StatePublished - 2002

Fingerprint

Tubulin
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
Proteins
taxane
Immunoglobulin Isotypes
Multiple Drug Resistance
Microtubules
Disease-Free Survival
Cross-Sectional Studies
Phenotype
Antibodies

ASJC Scopus subject areas

  • Cancer Research

Cite this

Dumontet, C., Isaac, S., Souquet, P. J., Bejui-Thivolet, F., Pacheco, Y., Peloux, N., ... Perol, M. (2002). Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Electronic Journal of Oncology, (1), 58-64.

Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. / Dumontet, Charles; Isaac, Sylvie; Souquet, Pierre Jean; Bejui-Thivolet, Françoise; Pacheco, Yves; Peloux, Nadine; Frankfurter, Anthony; Luduena, Richard; Perol, Maurice.

In: Electronic Journal of Oncology, No. 1, 2002, p. 58-64.

Research output: Contribution to journalArticle

Dumontet, C, Isaac, S, Souquet, PJ, Bejui-Thivolet, F, Pacheco, Y, Peloux, N, Frankfurter, A, Luduena, R & Perol, M 2002, 'Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy', Electronic Journal of Oncology, no. 1, pp. 58-64.
Dumontet, Charles ; Isaac, Sylvie ; Souquet, Pierre Jean ; Bejui-Thivolet, Françoise ; Pacheco, Yves ; Peloux, Nadine ; Frankfurter, Anthony ; Luduena, Richard ; Perol, Maurice. / Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. In: Electronic Journal of Oncology. 2002 ; No. 1. pp. 58-64.
@article{4535d154d637467e99416e1fa71618ec,
title = "Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy",
abstract = "This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total β tubulin, classes I, II and III β tubulin isotypes, δ2 alpha tubulin, τ protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-β tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. δ2 alpha tubulin, τ protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p=0.02). There were 2 responses to chemotherapy among 9 patients (22{\%}) with high levels of class III tubulin vs. 6 among 10 patients (60{\%}) with low levels of expression (Fisher exact test: p= 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.",
author = "Charles Dumontet and Sylvie Isaac and Souquet, {Pierre Jean} and Fran{\cc}oise Bejui-Thivolet and Yves Pacheco and Nadine Peloux and Anthony Frankfurter and Richard Luduena and Maurice Perol",
year = "2002",
language = "English (US)",
pages = "58--64",
journal = "Electronic Journal of Oncology",
issn = "1292-8933",
publisher = "Federation Nationale des Centres de Lutte contre le Cancer",
number = "1",

}

TY - JOUR

T1 - Expression of class III b tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy

AU - Dumontet, Charles

AU - Isaac, Sylvie

AU - Souquet, Pierre Jean

AU - Bejui-Thivolet, Françoise

AU - Pacheco, Yves

AU - Peloux, Nadine

AU - Frankfurter, Anthony

AU - Luduena, Richard

AU - Perol, Maurice

PY - 2002

Y1 - 2002

N2 - This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total β tubulin, classes I, II and III β tubulin isotypes, δ2 alpha tubulin, τ protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-β tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. δ2 alpha tubulin, τ protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p=0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p= 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

AB - This study determined the prevalence and the prognostic value of the expression of microtubule components in tumors of 19 patients with non small cell lung cancer receiving taxane-based regimens. Patient samples were stained with antibodies directed against total β tubulin, classes I, II and III β tubulin isotypes, δ2 alpha tubulin, τ protein, and the P-gp protein involved in the classical multidrug resistance phenotype. All tumors were stained with pan-β tubulin antibody and class I tubulin isotype. A majority of the tumor samples expressed class II and class III, although the percentage of positive cells varied significantly between tumors. δ2 alpha tubulin, τ protein and Pgp protein were found in only one tumor sample each. Progression-free survival was shorter (41 days) in patients whose tumors expressed high levels of class III tubulin isotype in comparison to patients with low levels (288 days, p=0.02). There were 2 responses to chemotherapy among 9 patients (22%) with high levels of class III tubulin vs. 6 among 10 patients (60%) with low levels of expression (Fisher exact test: p= 0.11). These data suggest that high expression of class III tubulin by tumor cells is associated with poor prognosis in patients with NSCLC receiving a taxane-based regimen.

UR - http://www.scopus.com/inward/record.url?scp=0037871319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037871319&partnerID=8YFLogxK

M3 - Article

SP - 58

EP - 64

JO - Electronic Journal of Oncology

JF - Electronic Journal of Oncology

SN - 1292-8933

IS - 1

ER -